Europe Insulin Infusion Pumps Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Europe Insulin Infusion Pumps Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The European insulin infusion pump market is expected to register a CAGR greater than 4% over the forecast period (2022-2027).

The COVID-19 pandemic has had a significant impact on the market studied. Type-1 diabetes patients have been more affected during the pandemic since people with diabetes have weak immune systems. People with diabetes are also more likely to face serious complications than normal people. The estimated cost per hospital admission during the first wave of COVID-19 in Europe ranged from EUR 25,018 for Type 2 diabetes patients with good glycemic control to EUR 57,244 for Type 1 diabetes patients with poor glycemic control. This reflects a higher risk of intensive care and ventilator support and a longer hospital stay. The estimated cost for patients without diabetes was EUR 16,993. The estimated total direct expenditure for secondary care for COVID-19 in Europe was EUR 13.9 billion. Therefore, diabetes treatment accounted for 23.5% of the total expenditures.

An insulin pump (also known as continuous subcutaneous insulin therapy) is a medical device used for the administration of insulin in the treatment of diabetes. Insulin pumps make it possible to deliver continuous infusion amounts of insulin at regular intervals. This is predicted to result in long-term cost savings relative to multiple daily injections. A conventional insulin pump includes the pump (including controls, a processing module, and batteries), a disposable reservoir for insulin (inside the pump), and a disposable infusion set, including a cannula for subcutaneous (under the skin) insertion and a tubing system to connect the insulin reservoir to the cannula. The configuration of the device may vary depending on the design. However, the application of infusion pumps across the world is increasing significantly.

The countries in Europe are facing a high burden of diabetes expenditure. According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. According to the same source, 21,600 children are added to the Type-1 diabetic population every year. These figures indicate that approximately 9% of the total healthcare expenditure in Europe is spent on diabetes. For patients relying on insulin pumps or multiple daily injections (MDI), CGM systems are an effective tool. They help in the improvement of glycemic balance without aggravating the danger of severe hypoglycemia.

In Europe, a variety of insulin pumps are available. Conventional insulin pumps have an insulin reservoir (or container) and a pumping mechanism attached to the body with tubing and an infusion set. Other insulin patch pumps are worn directly on the body and have a reservoir, pumping mechanism, and infusion set inside a small case. Patch pumps are controlled wirelessly by a separate device that allows the programming of insulin delivery from the patch. Most insurance companies in Europe cover insulin pump therapy with variable out-of-pocket expenses.

The technology associated with insulin pumps combines glucose monitoring using CGM with advanced algorithms to predict low glucose and suspend insulin delivery. The technological innovation in the insulin pumps market is likely to drive the market during the forecast period.

A study conducted in July 2020 in Germany found a significant increase in diabetic ketoacidosis and severe ketoacidosis in diabetes diagnosis in children and adolescents during the COVID-19 pandemic. The underlying causes for this increase may be multifactorial and reflect reduced medical services, fear of approaching the healthcare system, and other complex psychosocial factors. The German Center for Diabetes Research (DZD) conducts extensive scientific research to develop effective prevention and treatment measures to prevent the emergence or progression of diabetes. Around 11% of the people living in Germany have private health insurance. Only people who fulfill certain criteria can have private health insurance. For example, the gross income of the person seeking insurance must be above a certain threshold for at least one year. The developments in the insulin infusion pump reimbursement field are expected to bolster the adoption of insulin infusion pumps in Germany.

The new technologies in insulin infusion pump devices have driven the market studied. Animas had to exit the insulin pump market owing to the rising competition. Medtronic is the market leader and is expected to maintain its position during the forecast period.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support